Overview

DURECT is a biopharmaceutical company actively developing therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DUR 928, a new chemical entity in Phase 2 development, is the lead candidate in DURECT’s Epigenetic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival. Human applications may include acute organ injury, as seen in alcoholic hepatitis; other hepatic diseases, such as nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis; renal diseases; and inflammatory skin conditions such as psoriasis and atopic dermatitis. DURECT’s advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. Late-stage product candidates in this category include POSIMIR® (bupivacaine extended-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to 3 days of continuous pain relief after surgery, and ORADUR®-Methylphenidate ER, an investigational formulation of methylphenidate that has been approved in Taiwan for the treatment of attention deficit hyperactivity disorder (ADHD) as Methydur Sustained Release Capsules. In addition, for the assignment of certain patent rights related to its drug delivery technology, DURECT is set to receive single digit sales-based earn-out payments from U.S. net sales of PERSERIS™ (risperidone), which was approved by FDA in July 2018 for the treatment of schizophrenia in adults and is owned and marketed by Indivior PLC.

Stock Quote
NASDAQ DRRX (Common Stock)
$0.66 - 0.01
Dec 18, 2018 12:19 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent News | View All >
DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist

Read More

DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients

Read More

Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever DURECT Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 
Transfer Agent
Computershare Trust Company N.A.
250 Royall Street, Mailstop 3B
Canton, MA 02021
Phone: 781-575-3400

Accountants
Ernst & Young LLP
560 Mission Street, Suite 1600
San Francisco, CA 94105-2907
Phone: 415 894 8000
Fax: 415 894 8099